These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36481585)

  • 1. Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches.
    Tomar Y; Gorantla S; Singhvi G
    Drug Discov Today; 2023 Feb; 28(2):103465. PubMed ID: 36481585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in psoriasis research: From pathogenesis to therapeutics.
    Sugumaran D; Yong ACH; Stanslas J
    Life Sci; 2024 Oct; 355():122991. PubMed ID: 39153596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
    Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
    J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Navigating the landscape of psoriasis therapy: novel targeted pathways and emerging trends.
    Innani S; Tomar Y; Rana V; Singhvi G
    Expert Opin Ther Targets; 2023; 27(12):1247-1256. PubMed ID: 37997278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis.
    Wang H; Syrovets T; Kess D; Büchele B; Hainzl H; Lunov O; Weiss JM; Scharffetter-Kochanek K; Simmet T
    J Immunol; 2009 Oct; 183(7):4755-63. PubMed ID: 19752240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging landscape in psoriasis management: From topical application to targeting biomolecules.
    Rapalli VK; Singhvi G; Dubey SK; Gupta G; Chellappan DK; Dua K
    Biomed Pharmacother; 2018 Oct; 106():707-713. PubMed ID: 29990862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.
    Dragotto M; D'Onghia M; Trovato E; Tognetti L; Rubegni P; Calabrese L
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis, multi-omics research, and clinical treatment of psoriasis.
    Yu J; Zhao Q; Wang X; Zhou H; Hu J; Gu L; Hu Y; Zeng F; Zhao F; Yue C; Zhou P; Li G; Li Y; Wu W; Zhou Y; Li J
    J Autoimmun; 2022 Dec; 133():102916. PubMed ID: 36209691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased βTrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-κB signaling pathway.
    Li R; Wang J; Wang X; Zhou J; Wang M; Ma H; Xiao S
    Gene; 2016 Oct; 592(1):164-171. PubMed ID: 27476970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling.
    Li X; Xi B; Miao Y; Ma X; Zhang J; Gao J; Wei W; Zhou H; Yang C
    Int Immunopharmacol; 2021 Nov; 100():108129. PubMed ID: 34547680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target.
    Buerger C
    Front Immunol; 2018; 9():2786. PubMed ID: 30555471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Therapeutic Potential and Molecular Mechanism of Isoflavone Extract against Psoriasis.
    Li HJ; Wu NL; Lee GA; Hung CF
    Sci Rep; 2018 Apr; 8(1):6335. PubMed ID: 29679037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis: implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches.
    Todke P; Shah VH
    Int J Dermatol; 2018 Nov; 57(11):1387-1402. PubMed ID: 29923192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways.
    Kadagothy H; Nene S; Amulya E; Vambhurkar G; Rajalakshmi AN; Khatri DK; Singh SB; Srivastava S
    Eur J Pharmacol; 2023 May; 947():175668. PubMed ID: 36958476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions.
    Li Y; Cui H; Li S; Li X; Guo H; Nandakumar KS; Li Z
    Int Immunopharmacol; 2023 Jan; 114():109585. PubMed ID: 36527884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides.
    Li HJ; Wu NL; Pu CM; Hsiao CY; Chang DC; Hung CF
    Sci Rep; 2020 Feb; 10(1):2932. PubMed ID: 32076123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NF-κB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens.
    Moorchung N; Kulaar JS; Chatterjee M; Vasudevan B; Tripathi T; Dutta V
    Int J Dermatol; 2014 May; 53(5):570-4. PubMed ID: 23621342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH.
    Andrés RM; Montesinos MC; Navalón P; Payá M; Terencio MC
    J Invest Dermatol; 2013 Oct; 133(10):2362-2371. PubMed ID: 23594598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.
    Rafael A; Torres T
    Eur J Dermatol; 2016; 26(1):3-8. PubMed ID: 26552963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.